{"id":"https://openalex.org/W2005338042","doi":"https://doi.org/10.1002/bdd.581","title":"The new acyl\u2010CoA cholesterol acyltransferase inhibitor SMP\u2010797 does not interact with statins via OATP1B1 in human cryopreserved hepatocytes and oocytes expressing systems","display_name":"The new acyl\u2010CoA cholesterol acyltransferase inhibitor SMP\u2010797 does not interact with statins via OATP1B1 in human cryopreserved hepatocytes and oocytes expressing systems","publication_year":2007,"publication_date":"2007-10-08","ids":{"openalex":"https://openalex.org/W2005338042","doi":"https://doi.org/10.1002/bdd.581","mag":"2005338042","pmid":"https://pubmed.ncbi.nlm.nih.gov/17918775"},"language":"en","primary_location":{"id":"doi:10.1002/bdd.581","doi":"https://doi.org/10.1002/bdd.581","is_oa":false,"landing_page_url":"https://doi.org/10.1002/bdd.581","pdf_url":null,"source":{"id":"https://openalex.org/S57691945","display_name":"Biopharmaceutics & Drug Disposition","issn_l":"0142-2782","issn":["0142-2782","1099-081X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biopharmaceutics & Drug Disposition","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047891831","display_name":"Atsushi Kitamura","orcid":"https://orcid.org/0000-0003-0303-1198","observed_orcids":["https://orcid.org/0000-0003-0303-1198"]},"institutions":[{"id":"https://openalex.org/I31591830","display_name":"Sumitomo Dainippon Pharma (Japan)","ror":"https://ror.org/04sapgw72","country_code":"JP","type":"company","lineage":["https://openalex.org/I31591830"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Atsushi Kitamura","raw_affiliation_strings":["Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd, 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka, 554-0022, Japan. atsushi-kitamura@ds-pharma.co.jp","Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co. Ltd, 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka, 554-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd, 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka, 554-0022, Japan. atsushi-kitamura@ds-pharma.co.jp","institution_ids":["https://openalex.org/I31591830"]},{"raw_affiliation_string":"Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co. Ltd, 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka, 554-0022, Japan","institution_ids":["https://openalex.org/I31591830"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113942533","display_name":"Satoki Imai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I31591830","display_name":"Sumitomo Dainippon Pharma (Japan)","ror":"https://ror.org/04sapgw72","country_code":"JP","type":"company","lineage":["https://openalex.org/I31591830"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Satoki Imai","raw_affiliation_strings":["Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd, 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka, 554-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd, 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka, 554-0022, Japan","institution_ids":["https://openalex.org/I31591830"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049724669","display_name":"Masashi Yabuki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I31591830","display_name":"Sumitomo Dainippon Pharma (Japan)","ror":"https://ror.org/04sapgw72","country_code":"JP","type":"company","lineage":["https://openalex.org/I31591830"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masashi Yabuki","raw_affiliation_strings":["Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd, 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka, 554-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd, 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka, 554-0022, Japan","institution_ids":["https://openalex.org/I31591830"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036087532","display_name":"Setsuko Komuro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I31591830","display_name":"Sumitomo Dainippon Pharma (Japan)","ror":"https://ror.org/04sapgw72","country_code":"JP","type":"company","lineage":["https://openalex.org/I31591830"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Setsuko Komuro","raw_affiliation_strings":["Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd, 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka, 554-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd, 1-98 Kasugade-naka 3-chome, Konohana-ku, Osaka, 554-0022, Japan","institution_ids":["https://openalex.org/I31591830"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5047891831"],"corresponding_institution_ids":["https://openalex.org/I31591830"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":null,"fwci":0.3575,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.65762421,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"28","issue":"9","first_page":"517","last_page":"525"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9726999998092651,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9726999998092651,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.023399999365210533,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acyl-coa-cholesterol-acyltransferase-inhibitors","display_name":"acyl-CoA:cholesterol acyltransferase inhibitors","score":0.8889999985694885},{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.9039999842643738},{"id":"https://openalex.org/keywords/oatp1b1","display_name":"OATP1B1","score":0.9739999771118164},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9660000205039978},{"id":"https://openalex.org/keywords/hepatic-uptake","display_name":"hepatic uptake","score":0.5339999794960022},{"id":"https://openalex.org/keywords/pravastatin","display_name":"pravastatin","score":1.0},{"id":"https://openalex.org/keywords/cyclosporine","display_name":"cyclosporine","score":0.9279999732971191},{"id":"https://openalex.org/keywords/hepatocytes","display_name":"hepatocytes","score":0.49399998784065247},{"id":"https://openalex.org/keywords/oocytes","display_name":"oocytes","score":0.7360000014305115},{"id":"https://openalex.org/keywords/hyperlipidemia","display_name":"hyperlipidemia","score":0.7950000166893005}],"concepts":[{"id":"https://openalex.org/C2780499067","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin","level":2,"score":0.6270276308059692},{"id":"https://openalex.org/C2779519902","wikidata":"https://www.wikidata.org/wiki/Q1240093","display_name":"Pravastatin","level":3,"score":0.594737708568573},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5755260586738586},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5345240235328674},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.5116389393806458},{"id":"https://openalex.org/C2778670441","wikidata":"https://www.wikidata.org/wiki/Q384295","display_name":"Gemfibrozil","level":3,"score":0.5093492269515991},{"id":"https://openalex.org/C149011108","wikidata":"https://www.wikidata.org/wiki/Q652985","display_name":"Transporter","level":3,"score":0.4749757647514343},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.4146004617214203},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2951067388057709},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.29069212079048157},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.1267697513103485}],"mesh":[{"descriptor_ui":"D000068718","descriptor_name":"Rosuvastatin Calcium","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001667","descriptor_name":"Binding, Competitive","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001693","descriptor_name":"Biological Transport, Active","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004970","descriptor_name":"Estrone","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D004970","descriptor_name":"Estrone","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D005464","descriptor_name":"Fluorobenzenes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009287","descriptor_name":"Naphthyridines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D009865","descriptor_name":"Oocytes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D015925","descriptor_name":"Cryopreservation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016572","descriptor_name":"Cyclosporine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D017035","descriptor_name":"Pravastatin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D022781","descriptor_name":"Hepatocytes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D027361","descriptor_name":"Organic Anion Transporters","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D027361","descriptor_name":"Organic Anion Transporters","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D027361","descriptor_name":"Organic Anion Transporters","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D027381","descriptor_name":"Liver-Specific Organic Anion Transporter 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066298","descriptor_name":"In Vitro Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/bdd.581","doi":"https://doi.org/10.1002/bdd.581","is_oa":false,"landing_page_url":"https://doi.org/10.1002/bdd.581","pdf_url":null,"source":{"id":"https://openalex.org/S57691945","display_name":"Biopharmaceutics & Drug Disposition","issn_l":"0142-2782","issn":["0142-2782","1099-081X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biopharmaceutics & Drug Disposition","raw_type":"journal-article"},{"id":"pmid:17918775","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17918775","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biopharmaceutics & drug disposition","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W170029080","https://openalex.org/W1965161849","https://openalex.org/W1972250282","https://openalex.org/W1987183631","https://openalex.org/W2000055910","https://openalex.org/W2005368546","https://openalex.org/W2016169166","https://openalex.org/W2016713547","https://openalex.org/W2032320739","https://openalex.org/W2032890774","https://openalex.org/W2042531301","https://openalex.org/W2047207059","https://openalex.org/W2048593300","https://openalex.org/W2074862075","https://openalex.org/W2081656085","https://openalex.org/W2085448380","https://openalex.org/W2091146995","https://openalex.org/W2100323547","https://openalex.org/W2101008840","https://openalex.org/W2105813268","https://openalex.org/W2107423405","https://openalex.org/W2131483520","https://openalex.org/W2145804243"],"related_works":["https://openalex.org/W4408515180","https://openalex.org/W2942626091","https://openalex.org/W2312553284","https://openalex.org/W4392810634","https://openalex.org/W2028444358","https://openalex.org/W2086177595","https://openalex.org/W2066391465","https://openalex.org/W2010376251","https://openalex.org/W4317497451","https://openalex.org/W2110287784"],"abstract_inverted_index":{"It":[0],"is":[1,17,70,135],"possible":[2],"that":[3,24,97,137,195],"SMP-797":[4,35,48,161,196],"will":[5],"be":[6,20,73],"administered":[7],"frequently":[8],"in":[9,103,105],"combination":[10],"with":[11,37,101,146,202],"statins":[12,38,92,98,147,203],"to":[13,19,72,95,142,157,165,200],"hyperlipidemic":[14],"patients.":[15],"OATP1B1":[16,40,62,100,182],"thought":[18],"the":[21,26,45,86,126,171,175,186],"major":[22],"transporter":[23],"mediates":[25],"hepatic":[27],"uptake":[28,51,67,111,176],"of":[29,47,52,68,80,112,177],"statins.":[30],"This":[31],"study":[32],"investigated":[33],"whether":[34],"interacts":[36],"via":[39],"by":[41,55,59,125,160,179],"two":[42],"approaches.":[43],"Firstly,":[44],"effects":[46],"on":[49,148,204],"OATP1B1-mediated":[50,66,110,149],"estrone-3-sulfate":[53],"(ES)":[54],"human":[56],"hepatocytes":[57],"and":[58,76,117,185],"oocytes":[60,180],"expressing":[61,181],"were":[63,82,93],"examined.":[64],"Since":[65],"ES":[69],"known":[71],"biphasic":[74],"(high-":[75],"low-affinity":[77],"sites),":[78],"concentrations":[79],"[(3)H]ES":[81,102,113],"set":[83],"lower":[84],"than":[85,170],"respective":[87],"K(m)":[88],"values.":[89],"Two":[90],"representative":[91],"used":[94],"assure":[96],"share":[99],"this":[104,138,152],"vitro":[106],"system.":[107],"Rosuvastatin":[108],"inhibited":[109,119],"through":[114],"both":[115],"sites":[116],"pravastatin":[118],"a":[120,166],"high-affinity":[121],"site.":[122],"The":[123],"inhibition":[124,156],"positive":[127],"control":[128],"(cyclosporin":[129],"A)":[130],"was":[131,140,162,183,188],"significant.":[132],"Thus,":[133],"it":[134],"considered":[136],"system":[139],"applicable":[141],"examine":[143],"drug-drug":[144],"interaction":[145],"uptake.":[150],"In":[151,190],"condition,":[153],"no":[154],"apparent":[155],"each":[158],"site":[159],"observed":[163],"up":[164],"concentration":[167],"3,000-fold":[168],"higher":[169],"clinical":[172],"level.":[173],"Secondly,":[174],"[(14)C]SMP-797":[178],"examined":[184],"activity":[187],"negligible.":[189],"conclusion,":[191],"these":[192],"data":[193],"suggest":[194],"has":[197],"little":[198],"potential":[199],"interact":[201],"OATP1B1.":[205]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2021,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}